Journal of the American College of Surgeons · 13 Nov 2026
Posttransfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and RBCs During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma, Prehospital Blood Transfusion Coalition, National Association of Emergency Medical Services Physicians, Trauma Hemostasis and Oxygenation Research Network, and Allo Hope Foundation
Reynold Henry, Julia R Coleman, John B Holcomb, Daniel Lammers, Nakul Raykar, Zain G Hashmi, Randall Schaefer, Kevin Mackey, Eric Ernest, Rebecca Rimsza, Molly Sherwood, Philip C Spinella, Christopher D Barrett, Jeremy W Cannon, Martin J Schreiber, Mark H Yazer
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
BACKGROUND: Increasing use of low-titer group O whole blood and RBC in trauma resuscitation has increased the likelihood that RhD-negative females of childbearing potential (FCPs) will receive RhD-positive blood products. Concurrently, national trauma data demonstrate that FCPs with traumatic hemorrhage are approximately 40% less likely to receive low-titer group O whole blood than comparable male patients, highlighting a trauma systems and equity concern. Evidence-based guidance for posttransfusion management remains limited. STUDY DESIGN: A multidisciplinary panel representing trauma surgery, transfusion medicine, emergency medicine, critical care, OB, pediatrics, and prehospital care reviewed available literature, registry data, modeling studies, existing guidance, and ethical considerations and developed consensus recommendations through an iterative process for management of RhD-negative FCPs exposed to RhD-positive blood products during trauma resuscitation. RESULTS: Reported D-alloimmunization rates after trauma transfusion range from approximately 8% to 43%. Modeling studies estimate a perinatal death risk from anti-D-mediated hemolytic disease of the fetus and newborn (HDFN) of approximately 0.04% and a combined severe HDFN and perinatal death risk of approximately 0.24% after RhD-positive transfusion. Estimated risk of any HDFN-complicated future pregnancy ranges from approximately 0.6% to 6.5%. The panel concluded that RhD-positive blood products should not be withheld when RhD-negative products are unavailable, and transfusion is clinically indicated. Recommended management includes selective Rh immunoglobulin prophylaxis for low-volume exposures, structured antibody surveillance, patient counseling, multidisciplinary follow-up, and institutional protocols. CONCLUSIONS: For RhD-negative FCPs with life-threatening hemorrhage, immediate survival should take precedence over potential future reproductive risk. Standardized posttransfusion pathways may support equitable access to lifesaving transfusion while mitigating alloimmunization-related reproductive risks.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (24)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 4 more references
A free account opens the rest of the citing papers and references on every paper’s page.